JMS-17-2 is primarily used in scientific research focused on inflammation and immune response modulation. It acts as a selective inhibitor of 5-lipoxygenase-activating protein (FLAP), which plays a key role in the biosynthesis of leukotrienes—lipid mediators involved in inflammatory processes. Due to this mechanism, JMS-17-2 is employed in studies exploring the treatment of inflammatory diseases such as asthma, arthritis, and atherosclerosis. Its application allows researchers to probe leukotriene-dependent pathways and assess the therapeutic potential of targeting FLAP in preclinical models. The compound is not used clinically but serves as a valuable tool in pharmacological and biochemical research.